Schedule 33 Transitional arrangements: pharmacovigilance

1. 1Pharmacovigilance system master file
2. 2Paragraph 2
3. 3Post-authorisation safety studies
4. 4Paragraph 4
5. 5Reporting obligations
6. 6Paragraph 6
7. 7Paragraph 7
8. 8Paragraph 8
9. 9Periodic safety update reports
10. 10Paragraph 10